Topical Interferon Alfa-2b for Management of Ocular Surface Squamous Neoplasia in 23 Cases Outcomes Based on American Joint Committee on Cancer Classification
Topical Interferon Alfa-2b for Management of Ocular Surface Squamous Neoplasia in 23 Cases Outcomes Based on American Joint Committee on Cancer Classification
复制标题
DOI：
10.1001/archophthalmol.2011.385
复制
发表时间：
2012-02-01
影响因子：
--
通讯作者：
Shields, Carol L.
中科院分区：
文献类型：
--
作者：
Shah, Sanket U.;Kaliki, Swathi;Shields, Carol L.
目的：为了评价局部干扰素α-2b治疗眼表鳞状细胞瘤（OSSN）的疗效，对20例（23个肿瘤）临床可见的OSSN患者进行局部干扰素α-2b治疗，剂量为100万IU/mL，每日4次。肿瘤控制和并发症进行了评估，根据美国癌症联合委员会classification.Results：在19个肿瘤（83%）局部干扰素α-2b治疗后，中位时间为6个月（平均值，7个月，范围，1-12个月），并保持长达24个月的后续行动。在部分消退的4例肿瘤中（17%），肿瘤表面积在4个月（中位数）内减少了44%（中位数），无进一步缓解，并使用了替代治疗。根据美国癌症联合委员会分类，3种Tis中的2种（67%）、20种T3中的17种（85%）、23种N 0中的19种（83%）和23种M0中的19种（83%）类别肿瘤实现了完全控制。与未累及角膜的肿瘤相比，累及角膜的肿瘤反应更早（P= 0.01）。初始肿瘤大小与缓解时间无关（P= 0.27）。在3个月时观察到1例（Tis，4%）复发。不良反应包括结膜充血（2 [10%]）、滤泡肥大（2 [10%]）、巨大乳头状结膜炎（1 [5%]）、刺激（1 [5%]）、角膜上皮缺损（1 [5%]）和流感样症状（1 [5%]）;所有这些不良反应均在停药后1个月内消退。根据美国癌症联合委员会分类，局部干扰素α-2b可以在67%的Tis，85%的T3和83%的OSSN中实现完全控制。
Objective: To evaluate the efficacy of topical interferon alfa-2b in the management of ocular surface squamous neoplasia (OSSN).Methods: Clinically visible OSSN in 20 patients (23 tumors) was managed with topical interferon alfa-2b, 1 million IU/mL, 4 times daily. Tumor control and complications were evaluated according to American Joint Committee on Cancer classification.Results: Complete tumor resolution was achieved in 19 tumors (83%) following topical interferon alfa-2b treatment for a median period of 6 months (mean, 7 months; range, 1-12 months) and maintained for up to 24 months of follow-up. Of the 4 tumors with partial resolution (17%), tumor surface area was reduced 44% (median) during 4 months (median) without further response and alternative therapy was used. Based on American Joint Committee on Cancer classification, complete control was achieved in 2 of 3 Tis (67%), 17 of 20 T3 (85%), 19 of 23 N0 (83%), and 19 of 23 M0 (83%) category tumors. Tumors involving the cornea responded earlier compared with those without corneal involvement (P=.01). Initial tumor size did not correlate with time to response (P=.27). Recurrence was noted in 1 case (Tis, 4%) at 3 months. Adverse effects included conjunctival hyperemia (2 [10%]), follicular hypertrophy (2 [10%]), giant papillary conjunctivitis (1 [5%]), irritation (1 [5%]), corneal epithelial defect (1 [5%]), and flulike symptoms (1 [5%]); all resolved within 1 month of medication discontinuation.Conclusion: According to American Joint Committee on Cancer classification, complete control with topical interferon alfa-2b can be achieved in 67% of Tis, 85% of T3, and 83% of all OSSN.